Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses.
We have recently described a new antitumor treatment, electrochemotherapy (ECT), based on the large local potentiation of the effects of the chemotherapeutic agent bleomycin (BLM) by electric pulses (EP) delivered at the tumor site. We demonstrate here that the host's immune response participates in cure achievement. We obtain an increase of the rate of completely cured animals by injecting mice with interleukin-2 (IL-2).
Mir
L M
LM
Laboratoire de Biochimie-Enzymologie, Institut Gustave-Roussy, Villejuif, France.
Orlowski
S
S
Poddevin
B
B
Belehradek
J
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004599:Electric Stimulation Therapy; D007167:Immunotherapy; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D012513:Sarcoma, Experimental / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D001761:Bleomycin